Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2021 | FIRE-4.5: FOLFOXIRI plus either bevacizumab or cetuximab in mCRC

Sebastian Stintzing, MD, Charité Universitätsmedizin Berlin, Berlin, Germany, describes the findings of the Phase II FIRE-4.5 study (NCT04034459) of FOLFOXIRI (fluorouracil, leucovorin, oxaliplatin, and irinotecan) plus either bevacizumab or cetuximab as first-line treatment in patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC). FOLFOXIRI with bevacizumab resulted in a longer median progression-free survival (PFS) rate and a higher overall response rate (ORR), despite ORR as a primary endpoint not being met. Elderly patients and patients with right-sided colon cancers benefited from receiving FOLFOXIRI with bevacizumab the most. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.